A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

March 29, 2023

Study Completion Date

December 30, 2026

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Fenebrutinib

Fenebrutinib will be administered orally.

DRUG

Placebo

Placebo will be administered orally.

Trial Locations (17)

10000

Klinicki bolnicki centar Zagreb, Zagreb

Poliklinika Solmed, Zagreb

11000

Clinical Center of Serbia, Belgrade

11040

Military Medical Academy, Belgrade

11080

Clinical Hospital Centre Zemun, Zemun

18000

Clinical Center Nis, Niš

34000

Clinical center Kragujevac, Kragujevac

42000

General Hospital Varazdin, Varaždin

51000

Clinical Hospital Center Rijeka - PPDS, Rijeka

58633

Nemocnice Jihlava, Jihlava

78000

University Clinical Centre of the Republic of Srpska, Banja Luka

89106

Cleveland Clinic Lou Ruvo, Las Vegas

92835

Fullerton Neurology and Headache Center, Fullerton

656 91

Fakultni nemocnice u sv. Anny v Brne, Brno

500 05

Fakultni nemocnice Hradec Kralove, Hradec Králové

128 08

Vseobecna Fakultni Nemocnice V Praze - CRC - PPDS, Prague

821 01

Univerzitna nemocnica Bratislava, Bratislava

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY